{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T23:46:36Z","timestamp":1771890396476,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione e del Merito","doi-asserted-by":"publisher","award":["PE00000003"],"award-info":[{"award-number":["PE00000003"]}],"id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Since the introduction of an ethanol-free liquid levothyroxine formulation, only few studies assessed its therapeutic efficacy. The present study aimed to compare the efficacy of tablet (T-LT4) versus L-EF-LT4 in achieving the patient-specific TSH target in thyroidectomized patients. The primary objective was to assess whether the required LT4 dose differed between formulations in a real-life setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study was conducted on 275 patients who underwent total thyroidectomy and were treated with either T-LT4 (n\u2009=\u2009152) or L-EF-LT4 (n\u2009=\u2009123) between 2020 and 2023. Clinical and biochemical data, including LT4 dose, BMI, TSH levels, and potential causes of malabsorption, were collected. The primary endpoint was the pro-kg LT4 dose required to achieve individualized TSH targets. Multivariate regression analysis was used to evaluate predictors of LT4 requirement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At final follow-up, 227 patients (82.5%) achieved their TSH target and were under stable doses of LT4 with no significant difference in mean LT4 dose between groups (T-LT4: 1.54\u2009\u00b1\u20090.35\u2009\u00b5g\/kg\/day; L-EF-LT4: 1.60\u2009\u00b1\u20090.32\u2009\u00b5g\/kg\/day,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.160). TSH levels were comparable (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.311). Regression analysis showed that age and BMI were inversely correlated with LT4 dose, while a diagnosis of differentiated thyroid cancer was positively correlated with LT4 dose. Formulation type was not a significant predictor.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with post-surgical hypothyroidism, L-EF-LT4 demonstrated equivalent therapeutic efficacy to T-LT4 in terms of dose requirement and TSH control. These findings support the use of L-EF-LT4 as a viable alternative to tablet LT4, particularly in clinical scenarios where flexible timing of ingestion may improve patient compliance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12020-025-04375-9","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T18:33:50Z","timestamp":1754678030000},"page":"793-799","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of tablet versus liquid ethanol-free Levothyroxine in thyroidectomised patients"],"prefix":"10.1007","volume":"90","author":[{"given":"Laura","family":"Croce","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyridon","family":"Chytiris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marsida","family":"Teliti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Bertini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Pizzuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzia","family":"Dal Molin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Limiroli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetto","family":"Cal\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Magri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6464-2334","authenticated-orcid":false,"given":"Mario","family":"Rotondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"issue":"5","key":"4375_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrendo.2018.18","volume":"14","author":"PN Taylor","year":"2018","unstructured":"P.N. Taylor, D. Albrecht, A. Scholz, G. Gutierrez-Buey, J.H. Lazarus, C.M. Dayan et al., Global epidemiology of hyperthyroidism and hypothyroidism. Nat. Rev. Endocrinol. 14(5), 301\u2013316 (2018). https:\/\/doi.org\/10.1038\/nrendo.2018.18.","journal-title":"Nat. Rev. Endocrinol."},{"issue":"12","key":"4375_CR2","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1089\/thy.2014.0028","volume":"24","author":"J Jonklaas","year":"2014","unstructured":"J. Jonklaas, A.C. Bianco, A.J. Bauer, K.D. Burman, A.R. Cappola, F.S. Celi et al., Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid 24(12), 1670\u20131751 (2014). https:\/\/doi.org\/10.1089\/thy.2014.0028.","journal-title":"Thyroid"},{"issue":"1","key":"4375_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12020-019-02039-z","volume":"66","author":"F Magri","year":"2019","unstructured":"F. Magri, L. Chiovato, L. Croce, M. Rotondi, Thyroid hormone therapy for subclinical hypothyroidism. Endocrine 66(1), 27\u201334 (2019). https:\/\/doi.org\/10.1007\/s12020-019-02039-z.","journal-title":"Endocrine"},{"issue":"Suppl 2","key":"4375_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12325-019-01081-7","volume":"36","author":"LH Duntas","year":"2019","unstructured":"L.H. Duntas, Seven decades of levothyroxine: a comprehensive profile. Adv. Ther. 36(Suppl 2), 27\u201329 (2019). https:\/\/doi.org\/10.1007\/s12325-019-01081-7.","journal-title":"Adv. Ther."},{"key":"4375_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.626268","volume":"11","author":"P Miccoli","year":"2020","unstructured":"P. Miccoli, G. Materazzi, L. Rossi, Levothyroxine therapy in thyrodectomized patients. Front. Endocrinol. (Lausanne) 11, 626268 (2020). https:\/\/doi.org\/10.3389\/fendo.2020.626268.","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"3","key":"4375_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s12020-022-03289-0","volume":"80","author":"P Trimboli","year":"2023","unstructured":"P. Trimboli, N. Ossola, A. Torre, F. Mongelli, M. Quarenghi, C. Camponovo et al., The performance of levothyroxine tablet is impaired by bariatric surgery. Endocrine 80(3), 563\u2013569 (2023). https:\/\/doi.org\/10.1007\/s12020-022-03289-0.","journal-title":"Endocrine"},{"issue":"1","key":"4375_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12020-016-1035-1","volume":"54","author":"C Virili","year":"2016","unstructured":"C. Virili, P. Trimboli, F. Romanelli, M. Centanni, Liquid and softgel levothyroxine use in clinical practice: state of the art. Endocrine 54(1), 3\u201314 (2016). https:\/\/doi.org\/10.1007\/s12020-016-1035-1.","journal-title":"Endocrine"},{"key":"4375_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fendo.2018.00010","volume":"9","author":"C Virili","year":"2018","unstructured":"C. Virili, L. Giovanella, P. Fallahi, A. Antonelli, M.G. Santaguida, M. Centanni et al., Levothyroxine therapy: changes of TSH Levels by switching patients from tablet to liquid formulation. A systematic review and meta-analysis. Front. Endocrinol. (Lausanne) 9, 10 (2018). https:\/\/doi.org\/10.3389\/fendo.2018.00010.","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1","key":"4375_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12020-019-02049-x","volume":"66","author":"C Virili","year":"2019","unstructured":"C. Virili, P. Trimboli, M. Centanni, Novel thyroxine formulations: a further step toward precision medicine. Endocrine 66(1), 87\u201394 (2019). https:\/\/doi.org\/10.1007\/s12020-019-02049-x.","journal-title":"Endocrine"},{"issue":"12","key":"4375_CR10","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.1210\/jc.2014-2684","volume":"99","author":"R Vita","year":"2014","unstructured":"R. Vita, G. Saraceno, F. Trimarchi, S. Benvenga, Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors. J. Clin. Endocrinol. Metab. 99(12), 4481\u20134486 (2014). https:\/\/doi.org\/10.1210\/jc.2014-2684.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"4375_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s12020-017-1244-2","volume":"56","author":"S Benvenga","year":"2017","unstructured":"S. Benvenga, F. Di Bari, R. Vita, Undertreated hypothyroidism due to calcium or iron supplementation corrected by oral liquid levothyroxine. Endocrine 56(1), 138\u2013145 (2017). https:\/\/doi.org\/10.1007\/s12020-017-1244-2.","journal-title":"Endocrine"},{"issue":"2","key":"4375_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1089\/thy.2015.0422","volume":"26","author":"C Cappelli","year":"2016","unstructured":"C. Cappelli, I. Pirola, L. Daffini, A. Formenti, C. Iacobello, A. Cristiano et al., A double-blind placebo-controlled trial of liquid thyroxine ingested at breakfast: results of the TICO study. Thyroid 26(2), 197\u2013202 (2016). https:\/\/doi.org\/10.1089\/thy.2015.0422.","journal-title":"Thyroid"},{"issue":"6","key":"4375_CR13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1055\/s-0034-1384535","volume":"65","author":"M Giusti","year":"2015","unstructured":"M. Giusti, L. Mortara, N. Machello, E. Monti, G. Pera, M. Marenzana, Utility of a liquid formulation of levo-thyroxine in differentiated thyroid cancer patients. Drug. Res. (Stuttg.) 65(6), 332\u2013336 (2015). https:\/\/doi.org\/10.1055\/s-0034-1384535.","journal-title":"Drug. Res. (Stuttg.)"},{"issue":"1","key":"4375_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12020-016-1003-9","volume":"55","author":"CP Lombardi","year":"2017","unstructured":"C.P. Lombardi, R. Bocale, A. Barini, A. D\u2019Amore, M. Boscherini, R. Bellantone, Comparative study between the effects of replacement therapy with liquid and tablet formulations of levothyroxine on mood states, self-perceived psychological well-being and thyroid hormone profile in recently thyroidectomized patients. Endocrine 55(1), 51\u201359 (2017). https:\/\/doi.org\/10.1007\/s12020-016-1003-9.","journal-title":"Endocrine"},{"key":"4375_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7053959","volume":"2017","author":"C Cappelli","year":"2017","unstructured":"C. Cappelli, I. Pirola, E. Gandossi, C. Casella, D. Lombardi, B. Agosti et al., TSH variability of patients affected by differentiated thyroid cancer treated with levothyroxine liquid solution or tablet form. Int. J. Endocrinol. 2017, 7053959 (2017). https:\/\/doi.org\/10.1155\/2017\/7053959.","journal-title":"Int. J. Endocrinol."},{"issue":"2","key":"4375_CR16","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s12020-017-1311-8","volume":"59","author":"V Di Donna","year":"2018","unstructured":"V. Di Donna, R.M. Paragliola, C. de Waure, G. Papi, A. Pontecorvi, S.M. Corsello, Is levothyroxine requirement the same for tablet and soft gel formulations?. Endocrine 59(2), 458\u2013460 (2018). https:\/\/doi.org\/10.1007\/s12020-017-1311-8.","journal-title":"Endocrine"},{"key":"4375_CR17","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9043450","volume":"2016","author":"C Cappelli","year":"2016","unstructured":"C. Cappelli, I. Pirola, E. Gandossi, A. Cristiano, L. Daffini, B. Agosti et al., Thyroid hormone profile in patients ingesting soft gel capsule or liquid levothyroxine formulations with breakfast. Int. J. Endocrinol. 2016, 9043450 (2016). https:\/\/doi.org\/10.1155\/2016\/9043450.","journal-title":"Int. J. Endocrinol."},{"issue":"5","key":"4375_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/lio2.186","volume":"3","author":"P Fallahi","year":"2018","unstructured":"P. Fallahi, S.M. Ferrari, G. Materazzi, F. Ragusa, I. Ruffilli, A. Patrizio et al., Oral L-thyroxine liquid versus tablet in patients submitted to total thyroidectomy for thyroid cancer (without malabsorption): a prospective study. Laryngoscope Investig. Otolaryngol. 3(5), 405\u2013408 (2018). https:\/\/doi.org\/10.1002\/lio2.186.","journal-title":"Laryngoscope Investig. Otolaryngol."},{"issue":"3","key":"4375_CR19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/FTD.0b013e318217b69f","volume":"33","author":"P Colucci","year":"2011","unstructured":"P. Colucci, P. D\u2019Angelo, G. Mautone, C. Scarsi, M.P. Ducharme, Pharmacokinetic equivalence of a levothyroxine sodium soft capsule manufactured using the new food and drug administration potency guidelines in healthy volunteers under fasting conditions. Ther. Drug. Monit. 33(3), 355\u2013361 (2011). https:\/\/doi.org\/10.1097\/FTD.0b013e318217b69f.","journal-title":"Ther. Drug. Monit."},{"issue":"4","key":"4375_CR20","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/cpdd.608","volume":"8","author":"M Tanguay","year":"2019","unstructured":"M. Tanguay, J. Girard, C. Scarsi, G. Mautone, R. Larouche, Pharmacokinetics and comparative bioavailability of a levothyroxine sodium oral solution and soft capsule. Clin. Pharmacol. Drug. Dev. 8(4), 521\u2013528 (2019). https:\/\/doi.org\/10.1002\/cpdd.608.","journal-title":"Clin. Pharmacol. Drug. Dev."},{"issue":"2","key":"4375_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.5414\/CP202485","volume":"54","author":"D Al-Numani","year":"2016","unstructured":"D. Al-Numani, C. Scarsi, M.P. Ducharme, Levothyroxine soft capsules demonstrate bioequivalent pharmacokinetic exposure with the European reference tablets in healthy volunteers under fasting conditions. Int. J. Clin. Pharmacol. Ther. 54(2), 135\u2013143 (2016). https:\/\/doi.org\/10.5414\/CP202485.","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"1","key":"4375_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov et al., 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1), 1\u2013133 (2016). https:\/\/doi.org\/10.1089\/thy.2015.0020.","journal-title":"Thyroid"},{"issue":"6","key":"4375_CR23","doi-asserted-by":"publisher","first-page":"988","DOI":"10.4158\/EP12280.GL","volume":"18","author":"JR Garber","year":"2012","unstructured":"J.R. Garber, R.H. Cobin, H. Gharib, J.V. Hennessey, I. Klein, J.I. Mechanick et al., Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr. Pract. 18(6), 988\u20131028 (2012). https:\/\/doi.org\/10.4158\/EP12280.GL.","journal-title":"Endocr. Pract."},{"issue":"12","key":"4375_CR24","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1002\/sim.1783","volume":"23","author":"SA Julious","year":"2004","unstructured":"S.A. Julious, Sample sizes for clinical trials with normal data. Stat. Med. 23(12), 1921\u20131986 (2004). https:\/\/doi.org\/10.1002\/sim.1783.","journal-title":"Stat. Med."},{"issue":"6","key":"4375_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.eprac.2024.03.388","volume":"30","author":"C Seng Yue","year":"2024","unstructured":"C. Seng Yue, C. Scarsi, E. Bettazzi, G. Mautone, F.S. Celi, M. Ducharme, Proton pump inhibitors do not affect the bioavailability of a novel liquid formulation of levothyroxine. Endocr. Pract. 30(6), 513\u2013520 (2024). https:\/\/doi.org\/10.1016\/j.eprac.2024.03.388.","journal-title":"Endocr. Pract."},{"issue":"8","key":"4375_CR26","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1089\/thy.2021.0604","volume":"32","author":"M Ducharme","year":"2022","unstructured":"M. Ducharme, C. Scarsi, E. Bettazzi, G. Mautone, Y. Lewis, F.S. Celi, A novel levothyroxine solution results in similar bioavailability whether taken 30 or just 15\u2009min before a high-fat high-calorie meal. Thyroid 32(8), 897\u2013904 (2022). https:\/\/doi.org\/10.1089\/thy.2021.0604.","journal-title":"Thyroid"},{"issue":"22","key":"4375_CR27","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.3390\/jcm10225233","volume":"10","author":"K Bornikowska","year":"2021","unstructured":"K. Bornikowska, M. Gietka-Czernel, D. Raczkiewicz, P. Glinicki, W. Zgliczy\u0144ski, Improvements in quality of life and thyroid parameters in hypothyroid patients on ethanol-free formula of liquid levothyroxine therapy in comparison to tablet LT4 form: an observational study. J. Clin. Med. 10(22), 5233 (2021). https:\/\/doi.org\/10.3390\/jcm10225233.","journal-title":"J. Clin. Med."},{"issue":"1","key":"4375_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000508216","volume":"10","author":"GK Markantes","year":"2021","unstructured":"G.K. Markantes, K. Dimitropoulos, I. Mamali, I. Tseti, G. Sakellaropoulos, K.B. Markou et al., Therapeutic equivalence of a new preparation of liquid levothyroxine with tablets in patients with overt primary hypothyroidism. Eur. Thyroid. J. 10(1), 59\u201364 (2021). https:\/\/doi.org\/10.1159\/000508216.","journal-title":"Eur. Thyroid. J."},{"issue":"1","key":"4375_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13044-025-00236-9","volume":"18","author":"E Gatta","year":"2025","unstructured":"E. Gatta, V. Maltese, I. Pirola, E. Gandossi, I. Silvestrini, M. Ugoccioni et al., Are liquid levothyroxine formulations comparable? The LETI study. Thyroid. Res. 18(1), 17 (2025). https:\/\/doi.org\/10.1186\/s13044-025-00236-9.","journal-title":"Thyroid. Res."},{"key":"4375_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1386510","volume":"15","author":"SM Ferrari","year":"2024","unstructured":"S.M. Ferrari, A. Patrizio, V. Mazzi, F. Ragusa, C. Botrini, G. Elia et al., Lactose intolerance and levothyroxine malabsorption: a review of the literature and report of a series of patients treated with liquid L-T4 without lactose. Front. Endocrinol. (Lausanne) 15, 1386510 (2024). https:\/\/doi.org\/10.3389\/fendo.2024.1386510.","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"4375_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.626371","volume":"12","author":"P Fallahi","year":"2021","unstructured":"P. Fallahi, S.M. Ferrari, G. Elia, F. Ragusa, S.R. Paparo, A. Antonelli, L-T4 therapy in enteric malabsorptive disorders. Front. Endocrinol. (Lausanne) 12, 626371 (2021). https:\/\/doi.org\/10.3389\/fendo.2021.626371.","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"2","key":"4375_CR32","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s12020-019-02185-4","volume":"67","author":"M Castellana","year":"2020","unstructured":"M. Castellana, C. Castellana, L. Giovanella, P. Trimboli, Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy?. Endocrine 67(2), 281\u2013290 (2020). https:\/\/doi.org\/10.1007\/s12020-019-02185-4.","journal-title":"Endocrine"},{"issue":"1","key":"4375_CR33","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s11695-023-06970-z","volume":"34","author":"M Almukainzi","year":"2024","unstructured":"M. Almukainzi, R. AlQahtani, R. Alanazi, R. Alamri, H. Alayed, Insight of the biopharmaceutical implication of sleeve gastrectomy on levothyroxine absorption in hypothyroidism patients. Obes. Surg. 34(1), 192\u2013197 (2024). https:\/\/doi.org\/10.1007\/s11695-023-06970-z.","journal-title":"Obes. Surg."},{"issue":"1","key":"4375_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11695-016-2247-4","volume":"27","author":"P Fallahi","year":"2017","unstructured":"P. Fallahi, S.M. Ferrari, S. Camastra, U. Politti, I. Ruffilli, R. Vita et al., TSH normalization in bariatric surgery patients after the switch from L-Thyroxine in tablet to an oral liquid formulation. Obes. Surg. 27(1), 78\u201382 (2017). https:\/\/doi.org\/10.1007\/s11695-016-2247-4.","journal-title":"Obes. Surg."},{"issue":"1","key":"4375_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s12020-024-04016-7","volume":"87","author":"V Oteri","year":"2025","unstructured":"V. Oteri, S. Volpe, M. Lopes, G. Sceusa, A. Tumminia, A. Belfiore et al., Therapeutic efficacy and patient compliance of levothyroxine liquid and softgel formulations taken with meals: a systematic review. Endocrine 87(1), 48\u201358 (2025). https:\/\/doi.org\/10.1007\/s12020-024-04016-7.","journal-title":"Endocrine"},{"issue":"9","key":"4375_CR36","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3390\/children11091136","volume":"11","author":"R Ortolano","year":"2024","unstructured":"R. Ortolano, E. Cantarelli, F. Baronio, V. Assirelli, E. Candela, C. Mastrangelo et al., Comparison between liquid and tablet formulations in the treatment of congenital hypothyroidism up to 3 years of age: the first Italian study. Children (Basel) 11(9), 1136 (2024). https:\/\/doi.org\/10.3390\/children11091136.","journal-title":"Children (Basel)"},{"issue":"2","key":"4375_CR37","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4158\/EP161545.OR","volume":"23","author":"P Fallahi","year":"2017","unstructured":"P. Fallahi, S.M. Ferrari, A. Antonelli, In patients with subclinical hypothyroidism while in therapy with tablet L-T4, the liquid L-T4 formulation is more effective in restoring euthyroidism. Endocr. Pract. 23(2), 170\u2013174 (2017). https:\/\/doi.org\/10.4158\/EP161545.OR.","journal-title":"Endocr. Pract."},{"issue":"15","key":"4375_CR38","doi-asserted-by":"publisher","first-page":"4296","DOI":"10.3390\/jcm11154296","volume":"11","author":"R Bocale","year":"2022","unstructured":"R. Bocale, G. Desideri, A. Barini, A. D\u2019Amore, M. Boscherini, S. Necozione et al., Long-term adherence to levothyroxine replacement therapy in thyroidectomized patients. J. Clin. Med. 11(15), 4296 (2022). https:\/\/doi.org\/10.3390\/jcm11154296.","journal-title":"J. Clin. Med."},{"key":"4375_CR39","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3389\/fendo.2018.00699","volume":"9","author":"C Cappelli","year":"2018","unstructured":"C. Cappelli, R. Castello, F. Marini, A. Paoletta, M. Marchetti, M. Saullo et al., Adherence to levothyroxine treatment among patients with hypothyroidism: a Northeastern Italian Survey. Front. Endocrinol. (Lausanne) 9, 699 (2018). https:\/\/doi.org\/10.3389\/fendo.2018.00699.","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1","key":"4375_CR40","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1210\/jc.2004-1306","volume":"90","author":"F Santini","year":"2005","unstructured":"F. Santini, A. Pinchera, A. Marsili, G. Ceccarini, M.G. Castagna, R. Valeriano et al., Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J. Clin. Endocrinol. Metab. 90(1), 124\u2013127 (2005). https:\/\/doi.org\/10.1210\/jc.2004-1306.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"4375_CR41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4158\/EP09257.OR","volume":"16","author":"J Jonklaas","year":"2010","unstructured":"J. Jonklaas, Sex and age differences in levothyroxine dosage requirement. Endocr. Pract. 16(1), 71\u201379 (2010). https:\/\/doi.org\/10.4158\/EP09257.OR.","journal-title":"Endocr. Pract."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04375-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04375-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04375-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:07:38Z","timestamp":1761736058000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04375-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["4375"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04375-9","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author name \"Marzia Dal Molin\" has been updated in pubmed to reflect the surname as \"Dal Molin\"","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients signed an informed consent concerning the future use of their clinical-pathological data for research purposes. This study was formally approved by the Istituti Clinici Scientifici Maugeri IRCCS Ethical Committee (Protocol number CE 2418).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}